CCR5 and metabolic dysfunction-associated steatohepatitis: Recently, Friedman et al. reported that cenicriviroc, a dual antagonist of CCR2 and CCR5, showed a significant benefit in patients with non-alcoholic steatohepatitis with liver fibrosis65.